The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Official Title: A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
Study ID: NCT04910022
Brief Summary: Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Mayo Clinic Florida, Jacksonville, Florida, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
IRCCS Istituto Neurologico Carlo Besta, Milan, , Italy
Erasmus Medical Center, Rotterdam, , Netherlands
University Hospital Zurich, Zurich, , Switzerland